

25th September, 2006

Press Release

The Genetics Company Inc. enters distributorship agreement with i-DNA Genetics Pte Ltd.

The Genetics Company Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, is pleased to announce the closing of a distributorship agreement with i-DNA Genetics Pte Ltd, a subsidiary of i-DNA Biotechnology Pte Ltd, which is a leading Singapore-based supplier and distributor of research reagents and biochemicals. Within the scope of this agreement, The Genetics Company will supply i-DNA with its innovative beta-Amyloid (A β) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for exclusive distribution in Singapore and Malaysia and for non-exclusive distribution in several other Asian countries as well as in Australia and New Zealand.

Please find enclosed our press release. Thank you for your consideration and kind regards,



Dr. Harald Eistetter, CEO
eistetter@the-genetics.com

www.the-genetics.com

PRESS RELEASE

Zurich, Switzerland – 25th September, 2006

The Genetics Company Inc. enters distributorship agreement with i-DNA Genetics Pte Ltd.

The Genetics Company Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, is pleased to announce the closing of a distributorship agreement with i-DNA Genetics Pte Ltd, a subsidiary of i-DNA Biotechnology Pte Ltd., which is a leading Singapore-based supplier and distributor of research reagents and biochemicals. Within the scope of this agreement, The Genetics Company will supply i-DNA with its innovative beta-Amyloid (A β) detection tools for diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for exclusive distribution in Singapore and Malaysia, and for non-exclusive distribution in several other Asian countries as well as in Australia and New Zealand.

The Genetics Company's diagnostic and research tools enable the specific and selective detection of variants of human beta-Amyloid (A β), a key protein involved in the pathogenesis of several neurodegenerative diseases. The Company's products include very sensitive and reliable enzyme-linked immunosorbent assay (ELISA)-based test kits for the quantification of A β 40 and A β 42 in either cerebrospinal fluid (CSF) or plasma and cell lysate samples. While the corresponding A β 42/40 ratio has been validated by several recent studies as a superior biomarker for the diagnosis of incipient AD, the Company's test kits are also successfully used in clinical trials as drug monitoring tools or for pre-clinical research and development of A β lowering drugs. In addition, The Genetics Company's portfolio of A β -quantifying tools is complemented by highly selective monoclonal antibodies for the detection of A β , in particular A β 40 and A β 42.

Thuan D. Bui, CEO of i-DNA Genetics said: "In order to satisfy the increasing demand for high quality neurodegenerative disease research and diagnostic tools in Asia and Oceania, The Genetics Company's innovative products perfectly complete our portfolio of life science and biotech applications." Dr. Sebastian Breuer, Program Manager Diagnostics at The Genetics Company added: "With i-DNA centrally located in Singapore we have found an ideal partner and a hub to gain access to high-growth markets in Asia as well as to the well developed health care markets like Australia and New Zealand."

About i-DNA Biotechnology Pte Ltd.

i-DNA Genetics is a private limited company based in Singapore that strives to become a leading brand supplier of life sciences research products and customized contract research services. i-DNA is a distributor of life sciences and biotech research and biochemicals, equipment and instrument form leading manufacturers and suppliers worldwide. i-DNA is also a manufacturer of life sciences and biotech research products and provides customized contract research services. i-DNA addresses a growing interest in life sciences in Singapore

and in the Asia region as a whole. To achieve this, i-DNA has a core team, which altogether has more than 15 years of intensive scientific research experience, more than 10 years of direct sales & marketing, business and industrial experience in the field of biomedical sciences.

About The Genetics Company, Inc.

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and therapy monitoring of patients suffering from neurodegenerative disease and cancer. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-Amyloid converting enzyme). It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colon cancer. Headquartered in Zurich-Schlieren, Switzerland, the Company currently has 25 employees.

For additional information about i-DNA Genetics please contact:

*Dr. Thuan D. Bui
i-DNA Biotechnology
41 Science Park Road
#04-03A Gemini
Singapore Science Park II
Singapore 117610
Office: +65-6779 0665
Fax: +65-6776 0368
E-mail: thuan@i-dna.biz
Web: www.i-dna.biz*

For corporate information about The Genetics Company please contact:

*Dr. Harald Eistetter
The Genetics Company
Wagistrasse 27
CH-8952 Schlieren/Zürich
Switzerland
Tel: +41-44-2002222
Fax: +41-44-2002211
E-mail: eistetter@the-genetics.com
Web: www.the-genetics.com*

For further information about The Genetics Company's products please contact:

*Oliver Wildanger
The Genetics Company
Tel: +41-44-2002266
Fax: +41-44-2002211
E-mail: wild@the-genetics.com*